Clinical Observation of the Regimen for Nedaplain and Cisplatin Chemotherapy in the Treatment with Advanced Non-small Cell Lung Cancer
-
摘要: 目的:对比分析含奈达铂联合化疗方案和含顺铂联合化疗方案治疗中晚期非小细胞肺癌的疗效和不良反应。方法:70例中晚期非小细胞肺癌患者,其中奈达铂治疗组(A组)34例,顺铂治疗组(B组)36例。结果:A组有效率(32.35%)和B组有效率(34.28%)无显著差异(P>0.05);A组胃肠道反应(23.53%)发生率明显低于B组(69.44%)(P<0.01);两组肾脏毒性无明显差异;两组白细胞下降发生率分别为26.47%和25.00%,无显著差异;血小板下降A组(52.94%)较B组(27.78%)显著(P<0.05)。结论:奈达铂治疗中晚期非小细胞肺癌的有效率不低于顺铂,胃肠道毒性显著减轻,且从临床的实用性和便利性上考虑,奈达铂更容易为临床医生和患者所接受。Abstract: Objective: To detect the efficacy and the side effect of the regimen for combined chemotherapy with Nedaplatin and cisplatin in the treatment of advanced non- small cell lung carcinoma. Methods: A total of 70 patients with advanced non- small cell lung carcinoma were divided into the Nedaplatin group (group A, n=34) and the traditional group (group B, n=36). Results: The efficacy of group A was 32.35% and group B was 34.28%. There was no significant difference between the two groups in curative effect (P >0.05). A lower response rate of digestive reaction and nephrotoxicity (23.53%) occurred in group A, compared to that occurred in group B (69.44%), with a significant difference between the two groups (P<0.01). There was no significant difference between two groups in the incidence of leukopenia (26.47%, 25.00%) and response rate of nephrotoxicity (2.94%, 11.11%). There was a higher thrombocytopenia response rate (52.94%) in group A than in group B (27.78%), with a significant difference between the groups (P<0.05). Conclusions: There is no significant difference between Nedaplatin and Cisplatin regimens and there is a lower digestive reaction and nephrotoxicity response rate than in Cisplatin group. Considering that it is clinical pragmatic and convenient, Nedaplatin is easy to be accepted by the patients and clinicans both.
-
Keywords:
- Nedaplatin /
- cisplatin /
- Non-small-cell lung Cancer (NSCLC)
-
-
[1] 1 Matsumoto M,Takeda Y,Maki H.Preclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer[J].Japanese Journal of Cancer Research,2001,(01):51-58.
2 康欣梅,张清媛,赵文辉.紫杉醇联合表阿霉素与诺维本联合表阿霉素治疗晚期乳腺癌的临床对比观察[J].中国肿瘤临床,2004,(18):1040-1044.
3 Arriagada R,Bergman B,Dunant A.Cisplatin-based adjuvant chemotherapy in patients with completely resected nonsmall-cell lung cancer[J].New England Journal of Medicine,2004,(04):351-360.
4 Blum RH.Adjuvant chemotherapy for lung cancer-a new standard of care[J].New England Journal of Medicine,2004,(04):404-405.
5 徐瑞华,管忠震,姜文奇.奈达铂治疗非小细胞肺癌的Ⅱ期临床研究报告[J].癌症,2002,(12):1354-1358.
6 管忠震,徐瑞华.奈达铂临床研究进展[J].中国肿瘤临床,2004,(13):774-779.
7 Yamada H,Uchida N,Maekawa R.Sequence-dependent antitumor efficacy of combination chemotherapy with nedaplatin,a newly developed platinum,and paclitaxel[J].CANCER LETTERS,2001,(01):17-25.
8 Kanzawa F,Koizumi F,Koh Y.In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction[J].Clinical Cancer Research,2001,(01):202-209.
9 Fukuda M,Shinkai T,Eguchi K.Phase Ⅱ study of (glycolate-O,O) diamineplatinum (Ⅱ),a movel platinum complex,in the treatment of non-small lung cancer[J].Cancer Chemotherapy and Pharmacology,1990,(06):393-396.
10 胡晓桦,谢伟敏,刘志辉.奈达铂治疗耐药性鼻咽癌和非小细胞肺癌[J].中国癌症杂志,2003,(03):265-266.
11 Takigawa N,Segawa Y,Ueoka H.Combination of nedaplatin and vindesine for treatment of relapsed or refractory non-small-cell lung cancer[J].Cancer Chemotherapy and Pharmacology,2000,(04):272-278.
计量
- 文章访问数: 7
- HTML全文浏览量: 0
- PDF下载量: 3
下载:
